Phase II study of 6 -methylpregn-4-ene-3,11,20-trione (NSC-17256).
D000284:Administration, Oral; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007664:Ketosteroids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D011278:Pregnanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011283:Pregnenes; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011507:Proteinuria / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014062:Tongue Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D007664:Ketosteroids; D011278:Pregnanes; D011283:Pregnenes; C003491:6alpha-methylpregn-4-ene-3,11,20-trione